← Back to Clinical Trials
Recruiting NCT06288217

Non-invasive Trigeminal and Vagus Nerve Stimulation for Stroke Subjects With Chronic Upper Extremity Deficits

Trial Parameters

Condition Stroke, Ischemic
Sponsor NeuraStasis, Inc
Study Type INTERVENTIONAL
Phase N/A
Enrollment 25
Sex ALL
Min Age 40 Years
Max Age 80 Years
Start Date 2024-03-05
Completion 2024-12
Interventions
NeuraStasis Stimulator System (Non-Invasive Trigeminal and Vagus Nerve Stimulation)Upper Limb RehabilitationSham Stimulation

Brief Summary

This is a single-center, pilot study of up to 25 subjects with residual upper extremity deficits at least six months after an ischemic stroke. The purpose of the study is to evaluate the initial clinical safety, device functionality, and treatment effect of non-invasive electrical stimulation of the trigeminal and/or vagus nerves (nTVNS) using the NeuraStasis Stimulator System adjunctive to rehabilitation. Subjects will either receive the intervention or control-sham stimulation. The study will inform the design and implementation of a pivotal study.

Eligibility Criteria

Inclusion Criteria: * History of unilateral supratentorial ischemic stroke that occurred at least 6 months but not more than 10 years prior to enrollment. * Age \>40 years and \<80 years. * Fugl-Meyer Assessment, Upper Limb (FMA-UE) baseline score of 20 to 50 (inclusive of 20 and 50). * Ability to communicate, understand, and provide appropriate consent. Subjects should be able to follow two-step commands. * Right- or left-sided weakness of the upper extremity. Exclusion Criteria * Participant has implanted metallic or electronic devices in the head or neck * Hemorrhagic stroke or a heterogenous lesion etiology * Participant has a cardiac pacemaker or implanted or wearable defibrillator * Participant skin in the stimulation area has open wounds, skin eruptions, swollen, infected, or inflamed areas, or skin abnormalities that could be cancerous * Advanced cardiac, pulmonary, liver, kidney dysfunction or blood system disease * Participant has a fever or shows clinical signs concerning fo

Related Trials